News >

Pembrolizumab Prolongs Survival in Second-Line Urothelial Carcinoma

Virginia Powers, PhD
Published: Wednesday, Feb 01, 2017

Andrea Necchi

Andrea Necchi

Treatment with the PD-1 inhibitor pembrolizumab (Keytruda) significantly prolonged overall survival (OS) over investigators’ choice of chemotherapy in patients with recurrent advanced urothelial carcinoma, according to results reported at the 19th European Cancer Congress (ECCO 2017). Findings from the phase III Keynote-045 study support pembrolizumab as a new standard of care for patients with advanced urothelial carcinoma that progressed during or after platinum-base chemotherapy.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x